ERBB2 and breast carcinoma: Following the approval of rituximab in 1997 for the treatment of B-cell lymphoma, many others, including trastuzumab (approved in 1998 for HER2 overexpressing breast cancer) and cetuximab (approved in 2009 for colorectal cancers) were developed (1).